185 related articles for article (PubMed ID: 24740626)
1. Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab.
Jeng MR; Fuh B; Blatt J; Gupta A; Merrow AC; Hammill A; Adams D
Pediatr Blood Cancer; 2014 Nov; 61(11):2115-7. PubMed ID: 24740626
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
3. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
Koontz BF; Miles EF; Rubio MA; Madden JF; Fisher SR; Scher RL; Brizel DM
Head Neck; 2008 Feb; 30(2):262-6. PubMed ID: 17685450
[TBL] [Abstract][Full Text] [Related]
4. Vascular-targeted agents for the treatment of angiosarcoma.
Young RJ; Woll PJ; Staton CA; Reed MW; Brown NJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):259-70. PubMed ID: 24253175
[TBL] [Abstract][Full Text] [Related]
5. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
[TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
Saito W; Kase S; Fujiya A; Dong Z; Noda K; Ishida S
Retina; 2013 Oct; 33(9):1959-67. PubMed ID: 23652580
[TBL] [Abstract][Full Text] [Related]
7. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.
Rosen A; Thimon S; Ternant D; Machet MC; Paintaud G; Machet L
Br J Dermatol; 2010 Jul; 163(1):225-7. PubMed ID: 20394623
[No Abstract] [Full Text] [Related]
8. Unresectable angiosarcoma treated with bevacizumab and paclitaxel.
Nespereira-Jato MV; Peña-Panabad C; Quindós-Varela M; García-Silva J
Actas Dermosifiliogr; 2014 Jun; 105(5):520-2. PubMed ID: 24144236
[No Abstract] [Full Text] [Related]
9. Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature.
Nord KM; Kandel J; Lefkowitch JH; Lobritto SJ; Morel KD; North PE; Garzon MC
Pediatrics; 2006 Sep; 118(3):e907-13. PubMed ID: 16880251
[TBL] [Abstract][Full Text] [Related]
10. Intralesional bevacizumab for cutaneous capillary haemangioma associated with pregnancy.
Steeples LR; Bonshek R; Morgan L
Clin Exp Ophthalmol; 2013; 41(4):413-4. PubMed ID: 22957786
[No Abstract] [Full Text] [Related]
11. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
12. Primary angiosarcoma of the parotid gland arising from benign congenital hemangioma.
Damiani S; Corti B; Neri F; Collina G; Bertoni F
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jul; 96(1):66-9. PubMed ID: 12847446
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis as a therapeutic target in breast cancer.
Koutras AK; Starakis I; Lymperatou D; Kalofonos HP
Mini Rev Med Chem; 2012 Oct; 12(12):1230-8. PubMed ID: 22512568
[TBL] [Abstract][Full Text] [Related]
15. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.
Agulnik M; Yarber JL; Okuno SH; von Mehren M; Jovanovic BD; Brockstein BE; Evens AM; Benjamin RS
Ann Oncol; 2013 Jan; 24(1):257-63. PubMed ID: 22910841
[TBL] [Abstract][Full Text] [Related]
16. Development of antiangiogenic therapies for ovarian cancer.
Markowska A; Lubin J; Madry R; Markowska J
Eur J Gynaecol Oncol; 2013; 34(4):303-6. PubMed ID: 24020134
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
18. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
19. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
Pavlidis ET; Pavlidis TE
World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
[TBL] [Abstract][Full Text] [Related]
20. [The Use of anti-VEGF preparations and PDT in the treatment of retinal juxtapapillary hemangioma - a case report].
Matušková V; Vysloužilová D
Cesk Slov Oftalmol; 2014 Oct; 70(5):196-200. PubMed ID: 25640043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
